GENITOURINARY CANCERS

Deepak A. Kapoor, MD, Chairman and CEO of Integrated Medical Professionals, discusses how physicians can adapt to the new value-based payment models.

Renowned oncologist Charles G. Drake, MD, PhD, has joined NewYork-Pesbyterian/Columbia University Medical Center (CUMC).

Raoul Concepcion, MD, director, Comprehensive Prostate Center, discussed the best treatment option for a patient with metasatic castration-resistant prostate cancer (mCRPC) during the LUGPA Annual Meeting.

Raoul Concepcion, MD, director, Comprehensive Prostate Center, recently sat down with <em>Targeted Oncology </em>to discuss his treatment decisions for 2 patient scenarios in prostate cancer.

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses the future of biomarkers in prostate cancer.

Description of&nbsp;3 cases whereby significant septic complications occurred in the setting of abiraterone use that were associated with&nbsp;hypogammaglobulinemia.

With anaplastic thyroid cancer (ATC) being a rare disease that often has poor prognoses, researchers are seeking therapies for these patients that are more promising than surgery or radiation.

Bertram Yuh, MD,&nbsp;discussed the selection of surgery or radiation therapy in patients with localized disease, as well as the potential for using active surveillance with these patients.

Clayton S. Lau, MD, highlights the importance of active surveillance, the evolution of surgical techniques and radiation therapy, and the steps oncologists should take once early-stage prostate cancer progresses.

In an interview with <em>Targeted Oncology</em>, Tanya Dorff, MD, discussed developments in the upfront treatment of hormone-sensitive metastatic prostate cancer.

The combination of cabozantinib (Cabometyx) plus nivolumab (Opdivo) in patients with advanced/refractory genitourinary cancers demonstrated promising activity in the second-line setting and beyond at all dose levels tested.

Toni Choueiri, MD, discusses some of the ongoing clinical trials in metastatic renal cell carcinoma (mRCC).

The FDA has updated the label for enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC) to include new data from the phase II TERRAIN study, according to the codevelopers of the androgen receptor inhibitor, Astellas and Pfizer.

Rahul Tendulkar, MD, associate, Cleveland Clinic, discusses findings of a recent study looking at post-prostatectomy radiation and its impact on prostate cancer mortality.

Study results that examined patient-reported outcomes and quality of life measures demonstrate that hypofractionated radiotherapy (H-RT) is a viable, safe, and value-added alternative to patients with low-risk prostate cancer.

Men with bone-metastatic castration-resistant prostate cancer (mCRPC) appeared to derive additional benefits from treatment with radium-223 with concomitant bone-targeted therapies.

A move by CVS Health to place in-house physician dispensaries out-of-network for purposes of Medicare Part D drug payment would force hundreds of thousands of cancer patients across the country to find alternate sources for their oral oncolytic drugs, the Community Oncology Alliance (COA) argued in a new white paper.

The addition of external-beam radiotherapy (EBRT) to interstitial brachytherapy failed to reduce prostate cancer progression compared to brachytherapy alone in men with intermediate-risk disease, interim data from a randomized trial showed.

Although prostate cancer was among the first tumor types to be studied with immunotherapy treatments, prostate cancer appears to not be immunologic, according to Susan F. Slovin, MD, PhD.

Advances in the computerization of the imaging, blood flow, and tumor measures of exact volume and vessel density are now less operator dependent. That provides for an accurate and repeatable diagnosis, and a means to follow the individual patient&rsquo;s unique pattern of cancer development, progress, and response to treatment.

The European Commission (EC) has granted its approval for lenvatinib (Kisplyx; EU) in combination with everolimus (Afinitor) for patients with advanced renal cell carcinoma (RCC) following 1 prior VEGF-targeted therapy.

Though the current standard of care when treating muscle-invasive bladder cancer calls for neoadjuvant chemotherapy followed by radical cystectomy, the procedure is associated with a fair amount of morbidity and is not suggested lightly, according to Stanley Yap, MD.

Cell cycle progression (CCP) and homologous recombination deficiency (HRD) may be linked to bladder cancer recurrences and pathologic complete responses, according to Hristos Kaimakliotis, MD.

As a group, Rio Grande Urology shares a sense of obligation and culture. Its leaders have embraced an integrative model approach and sees the advantages of it. It was formed by 4 urology practices merging to build a main campus that houses the cancer center and radiation therapy center.